5 Safe Stocks to Buy for the Long Term in 2026

2. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 132

On May 26, BofA raised the firm’s price recommendation for Eli Lilly and Company (NYSE:LLY) to $1,251 from $1,133. It reiterated a Buy rating on the shares. The firm said it expects Lilly’s future revenue and profit growth to be driven by a doubling of GLP-1 U.S. market sales by 2033, the analyst told investors.

In separate news, Reuters reported on May 21 that Eli Lilly said its experimental obesity drug helped patients lose more than 28% of their weight over an 18-month period in a key clinical trial. The results could allow the company to seek regulatory approval and potentially launch the next-generation treatment next year.

The results were largely in line with Wall Street expectations and could position retatrutide as one of the most powerful weight-loss drugs in the growing obesity treatment market, where Lilly competes with Novo Nordisk.

Eli Lilly and Company (NYSE:LLY) is a medicine company that discovers, develops, manufactures, and markets pharmaceutical products through a single business segment focused on human pharmaceuticals.